RxDoctor Payments Data

Grace Pinto

Psychiatric/Mental Health · Pittsburgh, PANPI 1104438696

Payments from drug & device makers

$1,826in general payments, 2019–2025

Across 70 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$892
  • Alkermes, Inc.$358
  • Axsome Therapeutics, Inc.$160
  • Teva Pharmaceuticals USA, Inc.$124
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$65
  • Otsuka America Pharmaceutical, Inc.$65
  • plus $163 from 5 others

What the payments were for

  • Food & beverage$1,826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,826 in reported general payments places this provider in the 75th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$9,217
Medicare patients
25
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$40,568
TrintellixVortioxetine Hydrobromide39$22,755
QuviviqDaridorexant Hcl14$6,805
PristiqDesvenlafaxine Succinate12$5,169
Vilazodone Hcl22$3,062
Venlafaxine Hcl ErVenlafaxine Hcl156$2,389
Clozapine86$2,366
Atomoxetine Hcl33$2,278
Quetiapine Fumarate148$1,930
Duloxetine Hcl78$1,905
Olanzapine48$1,773
Lurasidone Hcl15$1,658
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine33$1,480
Bupropion XlBupropion Hcl73$1,448
Buspirone Hcl128$1,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$58$40,56813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$22,75539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →